VTE treatment in 2016 and future challenges
Prof. Mark Crowther talks about drugs used in thromboembolism treatment and emerging challenges in the field.
Prof. Mark Crowther talks about drugs used in thromboembolism treatment and emerging challenges in the field.
Prof. Hertzel Gerstein guides us through agents used in diabetes and reviews 2015 developments in the field.
Prof. Mark Crowther discusses recent milestones in the development of thromboembolism treatment.
Prof. Waleed Alhazzani shares his views on stress ulcer prophylaxis in critically ill patients.
Prof. Mark Crowther looks back at 2015 highlights in hematology and thromboembolism.
Prof. Hertzel Gerstein talks about target blood pressure in patients with type 2 diabetes in light of ACCORD and SPRINT trials.
Prof. Waleed Alhazzani discusses recent trials of early goal-directed therapy for septic shock.
Prof. Hertzel Gerstein discusses the effects of empagliflozin on serious health outcomes, including mortality.
Prof. James Douketis talks about managing perioperative cardiovascular risk, bleeding risk, and direct-acting oral anticoagulants.
Prof. James Douketis explains the questions behind the BRIDGE trial and its results (managing warfarin in the periprocedural and perioperative period).